IL6 and rheumatoid arthritis: In patients with rheumatoid arthritis, characterized by a substantial volume of IL-6 in both synovial fluid and serum, tocilizumab selectively binds to this cytokine, consequently alleviating the symptomatic manifestations of the disease.